Immix Biopharma, Inc.IMMXNASDAQ
Loading
Year-over-year SG&A expense growth
Latest
0.00%
↓ 100% vs avg
Percentile
P22
Within normal range
Streak
1 qtr
Consecutive declineDecelerating
Average
23.62%
Historical baseline
| Period | Value |
|---|---|
| Q4 2025 | 0.00% |
| Q3 2025 | 12.13% |
| Q2 2025 | 1.38% |
| Q1 2025 | -25.05% |
| Q4 2024 | 22.49% |
| Q3 2024 | 19.01% |
| Q2 2024 | 5.85% |
| Q1 2024 | 2.92% |
| Q4 2023 | -5.90% |
| Q3 2023 | 59.96% |
| Q2 2023 | 25.77% |
| Q1 2023 | -21.56% |
| Q4 2022 | 82.94% |
| Q3 2022 | -12.14% |
| Q2 2022 | 36.07% |
| Q1 2022 | 18.91% |
| Q4 2021 | 85.08% |
| Q3 2021 | 76.44% |
| Q2 2021 | 31.03% |
| Q1 2021 | 95.96% |
| Q4 2020 | 51.82% |
| Q3 2020 | 3.81% |
| Q2 2020 | -0.00% |
| Q1 2020 | 0.00% |